Junctophilins emerge as novel therapeutic targets.

J Cell Physiol

Institute of Pharmacy and Pharmacology, Learning Key Laboratory for Pharmacoproteomics, Hunan Province Cooperative Innovation Center for Molecular Target New Drugs Study, University of South China, Hengyang, China.

Published: August 2019

Junctophilins (JPs) emerge to play key role in human pathophysiology. This family includes four subtypes (JP1-4), which are differentially detected in excitable cells. Previous work demonstrated the knockout of JPs that seriously damage physiological functions in skeletal muscle, cardiac, and neurons. Here, we summarize latest papers on the essential function of JPs in some Ca -related diseases and neurological diseases, such as primary muscle disease, cardiomyopathies, Type 2 diabetes, gastrointestinal cancer, Huntington's disease-like 2, and Charcot-Marie-Tooth disease. Growing evidence suggests that targeting JPs might be a promising therapeutic approach to achieve better clinical efficacy in Ca -related diseases and neurological diseases.

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcp.28405DOI Listing

Publication Analysis

Top Keywords

-related diseases
8
diseases neurological
8
neurological diseases
8
junctophilins emerge
4
emerge novel
4
novel therapeutic
4
therapeutic targets
4
targets junctophilins
4
jps
4
junctophilins jps
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!